Terms: = Prostate cancer AND TPR, P12270, 7175 AND Treatment
13 results:
1. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary prostate cancer with prostate-Specific Membrane Antigen-Targeted
Wang F; Liu C; Vidal I; Mana-Ay M; Voter AF; Solnes LB; Ross AE; Gafita A; Schaeffer EM; Bivalacqua TJ; Pienta KJ; Pomper MG; Lodge MA; Song DY; Oldan JD; Allaf ME; De Marzo AM; Sheikhbahaei S; Gorin MA; Rowe SP
J Nucl Med; 2024 Jan; 65(1):87-93. PubMed ID: 38050147
[TBL] [Abstract] [Full Text] [Related]
3. Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation.
Min H; Dowling J; Jameson MG; Cloak K; Faustino J; Sidhom M; Martin J; Cardoso M; Ebert MA; Haworth A; Chlap P; de Leon J; Berry M; Pryor D; Greer P; Vinod SK; Holloway L
Radiother Oncol; 2023 Sep; 186():109794. PubMed ID: 37414257
[TBL] [Abstract] [Full Text] [Related]
4. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
[TBL] [Abstract] [Full Text] [Related]
5. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of Pathological Stage in Patients with prostate cancer: A Neuro-Fuzzy Model.
Cosma G; Acampora G; Brown D; Rees RC; Khan M; Pockley AG
PLoS One; 2016; 11(6):e0155856. PubMed ID: 27258119
[TBL] [Abstract] [Full Text] [Related]
7. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.
Inamoto T; Azuma H; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Kazuhiro S; Naito S; Namiki M; Nishimura K; Hirao Y; Usami M; Murai M; Akaza H;
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1197-204. PubMed ID: 24676427
[TBL] [Abstract] [Full Text] [Related]
8. Designed hybrid tpr peptide targeting Hsp90 as a novel anticancer agent.
Horibe T; Kohno M; Haramoto M; Ohara K; Kawakami K
J Transl Med; 2011 Jan; 9():8. PubMed ID: 21235734
[TBL] [Abstract] [Full Text] [Related]
9. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
Periyasamy S; Hinds T; Shemshedini L; Shou W; Sanchez ER
Oncogene; 2010 Mar; 29(11):1691-701. PubMed ID: 20023700
[TBL] [Abstract] [Full Text] [Related]
10. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment.
Pinkawa M; Fischedick K; Gagel B; Piroth MD; Asadpour B; Klotz J; Borchers H; Jakse G; Eble MJ
BMC Cancer; 2009 Aug; 9():296. PubMed ID: 19703300
[TBL] [Abstract] [Full Text] [Related]
11. Absence of cancer diagnosis and treatment in elderly Medicaid-insured nursing home residents.
Bradley CJ; Clement JP; Lin C
J Natl Cancer Inst; 2008 Jan; 100(1):21-31. PubMed ID: 18159068
[TBL] [Abstract] [Full Text] [Related]
12. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
[TBL] [Abstract] [Full Text] [Related]
13. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K
Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039
[TBL] [Abstract] [Full Text] [Related]
